

# QUANTIFICATION OF CIRCULATING NUCLEOSOMES USING NOVEL ASSAYS SHOWS ELEVATED LEVELS IN PATIENTS AFTER TRAUMATIC INJURY: A PILOT STUDY

Sergio M Navarro<sup>1</sup>, Riley Thompson<sup>1</sup>, Grant M. Spears<sup>1</sup>, Kent Bailey<sup>1</sup>, Leda Wang<sup>1</sup>, Mark Eccleston<sup>2</sup>, Terry Kelly<sup>2</sup>, Christine Wheeler<sup>2</sup>, Jing-Fei Dong<sup>3</sup>, Rosemary Kozar<sup>4</sup>, Myung S. Park<sup>1</sup>

<sup>1</sup>, Mayo Clinic, Department of Surgery, Division of Trauma Critical Care and General Surgery; <sup>2</sup>, VolitionRx Limited, Henderson, NV, US; <sup>3</sup>, Bloodworks Northwest Research Institute, Division of Hematology, School of Medicine, University of Washington; <sup>4</sup>, Shock Trauma Center, University of Maryland

## BACKGROUND

- The identification of reliable biomarkers to predict symptomatic VTE in trauma patients remains a clinical challenge. Citrullinated histones are elevated in trauma patients after injury; however, standardization of an assay for this biomarker is limited by its transient nature.<sup>1,2</sup>
- Nucleosomes have also been investigated, and by contrast, are stable in blood.<sup>3</sup> Quantification of nucleosomes, which are DNA wrapped around a histone protein core, has been shown to be a biomarker of sepsis, acute respiratory distress syndrome, and malignancy.<sup>4,5,6</sup>
- We hypothesized that levels of circulating nucleosomes quantified after traumatic injury, specifically histone H3.1 and its citrullinated R8 post-translation modification, would be greater in trauma patients than in healthy volunteers, and would be greater in those who develop VTE compared to those who did not.

## METHODS

- Trauma patients (pts) presenting to a Level I trauma center were evaluated for inclusion in a prospective case-cohort study. A subset of pts who developed incident, symptomatic VTE and of those who did not develop VTE within 90 days of discharge were selected in a 1:3 ratio, had samples collected within 12 hours injury, and were compared to pre-COVID-19 healthy volunteer samples as a non-trauma reference group. Circulating nucleosomes were quantified using Nu.Q® H3.1 and Nu.Q® H3R8 Cit assays, which has high consistency across lots, promoting standardization for translational use.

- Data were presented as median [IQR] or n (%), with Wilcoxon Rank-Sum or chi-squared test, with p-value <0.05 as statistically significant.


## RESULTS

- A total of 532 trauma pts were analyzed (52 years [32, 65], 70.7% male, 94.5% blunt, ISS 17 [9,27]): 126 pts with VTE to 406 with non-VTE. No significant differences were found in age, sex, or mechanism between pts with VTE and those without. However, VTE pts had greater ISS scores (14 [9,24], 2 [13, 34], p<0.001) and BMI (29.1 [24.0, 34.4], 27.6 [23.8, 32.2], p=0.030). A greater percentage of VTE pts underwent surgery (57.1%, 33.0%, p<0.001) and received blood transfusions within 24 hours of injury (52.4%, 23.6%, p<0.001).
- Both H3.1 and H3R8 Cit levels were greater in both groups of trauma patients than healthy volunteers (p<0.001). H3.1 levels were significantly greater in trauma patients who developed VTE compared to those who did not (p < 0.001), as were H3R8 Cit levels (p=0.012), Figure.

## CONCLUSION

- These findings suggest that neutrophil extracellular traps may contribute to the development of VTE observed after injury. Nucleosome levels of Nu.Q® H3.1 and Nu.Q® H3R8 Cit needs to be further investigated as an early biomarker potentially predictive of VTE.

FIGURE: NUCLEOSOME LEVELS IN VTE VS NON-VTE PATIENTS



## REFERENCES

- Goswami J, et al. Neutrophil Extracellular Trap Formation and Syndecan-1 Shedding Are Increased After Trauma. *Shock*. 2021 Sep 1;56(3):433-439.
- Navarro, S. M. et al. Increased citrullinated histone h3 levels and accelerated thrombin kinetics in trauma patients who develop venous thromboembolism. *Shock* 63, 441–447 (2025).
- Savchenko, A. S. et al. Neutrophil extracellular traps form predominantly during the organizing stage of human venous thromboembolism development. *J. Thromb. Haemost.* 12, 860–870 (2014).
- Su, F. et al. Circulating nucleosomes as a novel biomarker for sepsis: A scoping review. *Biomedicines* 12, 1385 (2024).
- Yehya, N., Thompson, J. & Mangalmurti, N. 15: Nucleosomes and nuclear DNA, but not mitochondrial DNA, are associated with pediatric ARDs mortality. *Crit. Care Med.* 50, 8–8 (2022).
- Van den Ackerveken, P. et al. Epigenetic profiles of elevated cell free circulating H3.1 nucleosomes as potential biomarkers for non-Hodgkin lymphoma. *Sci. Rep.* 13, 16335 (2023).
- Ghoneim, M., Fuchs, H. A. & Musselman, C. A. Histone tail conformations: A fuzzy affair with DNA. *Trends Biochem. Sci.* 46, 564–578 (2021).